INTCO Medical Wins the Listed Company Golden Bull Award · 2024 Golden Information Disclosure Award

Recently, at the Listed Company Golden Bull Awards selection organized by China Securities Journal, INTCO Medical (Stock Code: 300677) was honored with the “Listed Company Golden Bull Award · 2024 Golden Information Disclosure Award.” The award recognizes listed companies that demonstrate outstanding performance in information disclosure, investor relations management, and corporate governance, and represents a strong endorsement by the capital market of a company’s transparency and regulatory compliance.

INTCO Medical has long been committed to building a high-standard, transparent, and well-regulated information disclosure system. Guided by the principles of truthfulness, accuracy, completeness, timeliness, and fairness, the Company strictly complies with securities regulatory requirements. Through compliant and timely data disclosure, comprehensive periodic reports and interim announcements, as well as open and effective investor communication mechanisms, INTCO Medical has continuously enhanced the quality and transparency of its information disclosure, providing investors and market participants with clear, reliable information and strong confidence support.

In terms of institutional development, INTCO Medical has steadily improved its internal information disclosure processes and review mechanisms, strengthened the professional capabilities of its board secretary and finance teams, and incorporated information disclosure as a core element of corporate governance. These efforts ensure the timely, secure, and comprehensive disclosure of operating performance, material events, and key decision-making matters.

Collectively, these measures have not only improved disclosure efficiency, but also strengthened the capital market’s understanding of and trust in the Company’s operations.

The receipt of the 2024 Golden Information Disclosure Award is both a high-level recognition of INTCO Medical’s information disclosure practices and a strong affirmation of its continuous progress in governance capability, standardized operations, and investor relations management.

As a leading enterprise in China’s medical protective products industry, INTCO Medical continues to enhance its core business competitiveness while steadily optimizing corporate governance and capital market performance. By maintaining a robust information disclosure framework and actively advancing ESG practices, the Company has set a positive example for the capital market. Looking ahead, INTCO Medical will remain committed to high-quality development, further elevating its information disclosure standards, expanding investor engagement, and deepening its social responsibility initiatives, thereby contributing to sustainable industry growth and the healthy development of the capital market.